ATC kod: B02BD02
Det saknas publicerade kontrollerade studier om skillnader mellan könen avseende effekt, säkerhet och farmakokinetik för damoktokog alfa pegol.
Damoctocog alfa pegol is a pegylated recombinant factor VIII product used in treatment of acute bleeding episodes, perioperative management and routine prophylaxis in previously treated patients with hemophilia A [1]. Hemophilia A (deficiency in coagulation factor VIII) is an inherited X-linked disease and thus affects primarily men although women also can be affected (for example because of skewed inactivation of chromosome X) [2]. The occurrence of hemophilia A in women is very rare and data in women is not available [1].
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of damoctocog alfa pegol have been found.
No studies with a clinically relevant sex analysis regarding the efficacy of damoctocog alfa pegol have been found.
No studies with a clinically relevant sex analysis regarding the safety of damoctocog alfa pegol have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Nästan enbart män hämtade ut läkemedel innehållande koagulationsfaktor VIII (ATC-kod B02BD02) på recept i Sverige år 2020, totalt 428 män och 3 kvinnor [3].
Uppdaterat: 2021-06-07
Litteratursökningsdatum: 2021-05-25
Faktagranskat av: Diana Rydberg
Godkänt av: Karin Schenck-Gustafsson